Lung Cancer

Lung Cancer Isotype

Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Adenocarcinoma
Large-Cell Lung Carcinoma
Small-Cell Lung Cancer
Small-Cell Lung Cancer

HER2-Targeted

Pan-HER TKIs
Afatinib
Neratinib
Dacomitinib
Selective HER2 TKIs
Pyrotinib dimaleate
Poziotinib
Sunvozertinib
Anti-HER2 Antibodies
Trastuzumab
Pertuzumab

ALK-Targeted

First-Generation ALK-TKIs [1]
Crizotinib
Second-Generation ALK-TKIs [1]
Ceritinib
Alectinib
Brigatinib
Ensartinib dihydrochloride
Third-Generation ALK-TKIs [1]
Lorlatinib 

EGFR-Targeted

First-Generation EGFR-TKIs [2]
Erlotinib
Gefitinib
Lapatinib
Icotinib
Second-Generation EGFR-TKIs [2]
Afatinib
Dacomitinib
Neratinib
Poziotinib
Third-Generation EGFR-TKIs [3] [4]
Osimertinib
Mobocertinib
Rociletinib
Olmutinib
Nazartinib
Alflutinib mesylate
Almonertinib
Lazertinib
Fourth-Generation EGFR-TKIs [3]
EAI045
BLU-945
CH7233163
TQB3804
Anti-EGFR Antibodies
Cetuximab
Panitumumab
Necitumumab

MET-Targeted

Type I MET-TKIs [5]
Crizotinib
Capmatinib
Tepotinib
Savolitinib
Type II MET-TKIs [5]
Cabozantinib
Merestinib
Type III MET-TKIs [5]
Tivantinib

ROS1-Targeted

First-Generation ROS1-TKIs [6]
Crizotinib
Second-Generation ROS1-TKIs [6]
Ceritinib
Repotrectinib
Third-Generation ROS1-TKIs [6]
Lorlatinib 

BRAF-Targeted

First-Generation (Type I) BRAF Inhibitors [7]
Vemurafenib
Dabrafenib
Encorafenib
Next-Generation (Type II) BRAF Inhibitors [7]
AZ 628
LY3009120
Belvarafenib
CCT196969
Tovorafenib
Naporafenib
PLX7904
PLX8394

RET-Targeted

Selective RET Inhibitors
Selpercatinib
Pralsetinib
Non-Selective RET Inhibitors
Cabozantinib
Vandetanib
Lenvatinib
Regorafenib